Catalog No.S8591

For research use only.

FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.

FX1 Chemical Structure

CAS No. 1426138-42-2

Selleck's FX1 has been cited by 6 Publications

Purity & Quality Control

Choose Selective Bcl-6 Inhibitors

Biological Activity

Description FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.
Features Recommend for freshly prepared each time for in vitro experiment
BCL6 BTB [1]
(Cell-free assay)
35 μM
In vitro

FX1 disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, and mimicked the phenotype of mice engineered to express BCL6 with corepressor binding site mutations. FX1 suppressed ABC-DLBCL cells in vitro and in vivo, as well as primary human ABC-DLBCL specimens ex vivo. FX1 is specific to BCL6 and binds with a greater affinity than the natural BCL6 ligand SMRT. FX1 almost invariantly induced significant derepression of these genes(BCL6 target genes CASP8, CD69, CXCR4, CDKN1A, and DUSP5) as compared with vehicle in 2 independent DLBCL cell lines. FX1 was more than 100-fold more powerful than the previous generation of BCL6 inhibitors represented by 79-6, and 300-fold more potent than the recently reported binding of the antibiotics rifamycin and rifabutin (KD ~1 mM)[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TMD8 NHfxcHVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXWzJIRigXN? M1y4VmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRmNNPiCmZYDlcoRmdnRiaIXtZY4hXE2GODDj[YxteyCjZoTldkA{KGSjeYOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDFyIN88UU4> NFzPPGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES4OVk{PCd-Mki0PFU6OzR:L3G+
SUDHL4 MkTYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXGzJIRigXN? MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLDUFYh\GWyZX7k[Y51KGi3bXHuJHNWTEiONDDj[YxteyCjZoTldkA{KGSjeYOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDFyIN88UU4> NGfnZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES4OVk{PCd-Mki0PFU6OzR:L3G+
OCI-LY19 NGi1TpFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFTCR4o{KGSjeYO= NV;TfJFDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS0x4IHnu[IVx\W6mZX70JIh2dWGwIF;DTU1NYTF7IHPlcIx{KGGodHXyJFMh\GG7czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOTBizszNMi=> M3[4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEi1PVM1Lz5{OES4OVk{PDxxYU6=
OCI-LY10 M{jCWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MlG4N{Bl[Xm| NHT1W2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJEVDZiZHXw[Y5l\W62IHj1cYFvKE:FST3MXVExKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBIUTVyIE2gNVIvPTh7MjFOwG0v NELJUG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES4OVk{PCd-Mki0PFU6OzR:L3G+
SU-DHL-2 M2jyVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1n2U|Mh\GG7cx?= NYTaXopWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS0x4IHTldIVv\GWwdDDoeY1idiCVVT3ETGwuOiClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFEzNjV6OUKg{txONg>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6NUmzOEc,Ojh2OEW5N|Q9N2F-
U2932 NUnCXY5CSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mn33N{Bl[Xm| MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLDUFYh\GWyZX7k[Y51KGi3bXHuJHUzQTN{IHPlcIx{KGGodHXyJFMh\GG7czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOTJwNUi5NkDPxE1w MkTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OEW5N|QoRjJ6NEi1PVM1RC:jPh?=
KARPAS422 MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3fGdlMh\GG7cx?= M2PxU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRmNNPiCrbnTldIVv\GWwdDDoeY1idiCNQWLQRXM1OjJiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAyOi53OEmyJO69VS5? NVTXRYx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFU6OzRpPkK4OFg2QTN2PD;hQi=>
OCI-LY1 NYrhdYpKSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NH3PWJE{KGSjeYO= MkjhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCR2w3KGSncHXu[IVvfCCqdX3hckBQS0lvTGmxJINmdGy|IHHmeIVzKDNiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMUmuPVUzPiEQvF2u MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6NUmzOEc,Ojh2OEW5N|Q9N2F-
OCI-LY3 MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYWzJIRigXN? NFm3XGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJEVDZiZHXw[Y5l\W62IHj1cYFvKE:FST3MXVMh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGdKPTBiPTCxPU46PTJ4IN88UU4> M{XFTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEi1PVM1Lz5{OES4OVk{PDxxYU6=
AMO1 NFS2O2FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= Mn36N{Bl[Xm| NHHpZ|hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJEVDZiZHXw[Y5l\W62IHj1cYFvKEGPT{GgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSBzOT65OVI3KM7:TT6= M{L3T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEi1PVM1Lz5{OES4OVk{PDxxYU6=
In vivo

Low doses of FX1 induce regression of established tumors in mice bearing DLBCL xenografts. The half-life is estimated to be approximately 12 hours for FX1 in SCID mice. No signs of toxicity, inflammation, or infection are evident from H&E-stained sections of lung, gastrointestinal tract, heart, kidney, liver, spleen, and bone marrow of the fixed organs from mice treated with FX1 compared with vehicle. Peripheral blood counts and serum chemistry in FX1-treated mice are also examined and they remain within normal parameters. FX1 causes profound and significant suppression of DLBCLs in DLBCL xenografts, and indeed not only prevented growth of the xenografts but in addition causes these tumors to shrink from their initial volume. The maximal effect is already achieved by the lower 25 mg/kg dose. TUNEL and Ki-67 staining shows that FX1 also induced more apoptosis and growth arrest than 79-6, respectively[1].

Protocol (from reference)

Cell Research:


  • Cell lines: DLBCL cells, SUDHL-6 cells
  • Concentrations: 50 μM
  • Incubation Time: 30 min
  • Method:

    Quantitative ChIP is performed in SUDHL-6 cells exposed to FX1 (black bars) or vehicle (white bars) in DLBCL cells using antibodies for BCL6, SMRT, BCOR, or IgG control to enrich for known BCL6 binding sites in the CD69, CXCR4, and DUSP5 loci, or a negative control region.

Animal Research:


  • Animal Models: SCID mice bearing SUDHL-6 xenografts
  • Dosages: 50 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 368.82


CAS No. 1426138-42-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC2=NC(=O)C(=C2C=C1Cl)C3=C(N(C(=S)S3)CCC(=O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02902679 Completed Drug: BMS-986177 Thrombosis|Factor XI|Renal Impairment|ESRD (End-Stage Renal Disease) Bristol-Myers Squibb November 2016 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy FX1 | FX1 supplier | purchase FX1 | FX1 cost | FX1 manufacturer | order FX1 | FX1 distributor